comprehensive -WSS

comprehensive

author：fashion 2025-10-02 01:07:39 - browse：62651

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Dramatically reducing cancer deaths requires the PASTEUR Act

focus

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

Why depression after traumatic brain injury is distinct

Readout Newsletter: CAR

ProMED, early warning system on disease outbreaks, in peril

Male and female sex labels in research insufficient, scientists say

2 US Navy sailors arrested for allegedly spying for China

focus

comprehensive

focus

Novavax promises a turnaround & Lilly roils the obesity market

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Virginia high school admissions case could be legal follow

A cyberattack has disrupted hospitals and health care in several states

DIEP, the 'gold standard' of breast reconstruction, is under threat

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

Hepatitis C has a cure — but many Americans still lack access to it

White House drug shortage group privately met with industry

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

White House drug shortage group privately met with industry

knowledge

ProMED, early warning system on disease outbreaks, in peril

John Green on his newest strategy for fighting tuberculosis

My superpower is killing ticks

First U.S. drug developed to treat liver disease MASH is approved

Nearly two

Pushing for an NIH office for post

explore

focus

leisure time

hotspot